Secukinumab (Cosentyx)

[Guide]

Secukinumab has been in clinical trial since 2017. A recent update from Healio states, "Patients treated with secukinumab for papulopustular rosacea saw significant improvements in quality of life and reduction of severity markers, according to a study presented at the American Academy of Dermatology virtual meeting." [1]

Cosentyx is the brand name for secukinumab, which "is a human IgG1κ monoclonal antibody that binds to the protein interleukin (IL)-17A, and is marketed by Novartis for the treatment of psoriasis, ankylosing spondylitis, and psoriatic arthritis. It inhibits a member of the cytokine family, interleukin 17A." [2] 

"Secukinumab is a recombinant fully human IgG1/kappa monoclonal antibody and is manufactured in Chinese hamster ovary cells." [2]

"Study participants received 300 mg of secukinumab weekly for five weeks, and then monthly for two months....Among the 17 patients who were available for the final analysis, results showed a significant reduction in papule count at the 16-week follow-up, with a median decrease of -5 papules." [3]

How does Cosentyx work? 
The following video, while it explains how it works for psoriasis, the principles shown in the animated video explain how it works for rosacea. 

The Cosentyx Connect Personal Support Program may help in savings and other options. 

Anecdotal Reports

There is a thread at RF where at least two anecdotal reports of using Cosentyx is reported. [4]

Reply to this Topic
There is a reply to this topic button somewhere on the device you are reading this post. 

End Notes 

[1] Clinical Trials, Third Post, RRDi 

[2]  Secukinumab, Wikipedia

[3] IL-17 inhibition a path of interest in rosacea treatment, July 8, 2020, Ilya Petrou, M.D., Dermatology Times

[4] Jedimaster2cool started the thread and Dan3dwards reports he has joined the clinical trial in this thread at RF.